The record
| Class | sexual function |
|---|---|
| Also known as | PT-141, Vyleesi |
| Chain length | - |
| Molecular weight | 1,025.2 Da |
| Half-life | 2.7 hours |
| Route | SC (abdomen or thigh) |
| Studied for | FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women |
| Research use | Sexual dysfunction research, CNS melanocortin studies, Appetite/metabolism research |
| What has been shown | Increased sexual desire in HSDD; Enhanced arousal and satisfaction; Efficacy in both women and men (off-label); No significant cardiovascular effects |
| How it works | Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist with high affinity for MC4R and MC1R. Unlike other melanocortins, it acts centrally in the CNS to modulate sexual arousal pathways without significantly affecting blood pressure. Activates hypothalamic and limbic structures involved in sexual response. |
| Patent status | Palatin Technologies patents |
| Regulatory status | FDA approved (2019) |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Melanocortin Pathway Signaling (affection, 78%)
- Erythropoietic protoporphyria - FDA approved (illness, 30%)
- FDA-approved for hypoactive sexual desire disorder in premenopausal women (illness, 100%)
- Polymorphous light eruption (illness, 30%)
- Solar urticaria (illness, 30%)
- Vitiligo (illness, 30%)
- Low libido (symptom, 50%)